La cadena de opciones muestra datos clave de las opciones de acciones de Polestar Automotive a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Polestar Automotive..

Polestar Automotive (NASDAQ:PSNY) Bolsa, Cadena de Opciones

Polestar Automotive

Polestar Automotive Holding UK PLC operates as an electric vehicle manufacturer. It engages in designing products that are engineered to excite consumers and drive change. Polestar defines market-leading standards in design, technology, and sustainability. Polestar was established as a premium electric car brand by Volvo Cars and Geely Holdings. Polestar has produced two electric performance cars namely Polestar 1 and Polestar 2. Geographically, it derives a majority of revenue from USA.

Equities

News

Guidance

Movers

HAIL

PSNY

Polestar Automotive registra una caída del 10 % en ingresos del tercer trimestre y ajusta su plan de negocios hasta 2027.

Polestar reporta caída de ingresos: Acciones de PSNY se desploman

Markets

General

ARKX

Polestar registra un aumento del 5,3% en las ventas al por menor en el 4T de 2024, pero reporta una caída del 15% en el total anual.

Ventas de Polestar aumentan 5,3% en el 4T, pero caen un 15% en 2024

Polestar Automotive Holding UK Limited - Class A ADS

Polestar Automotive Holding UK PLC

Polestar Automotive Holding UK Limited - Class C-1 ADS (ADW)

<p>On Thursday, <strong>GE HealthCare</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>) reported fourth-quarter adjusted EPS of $1.45, up from $1.18 a year ago, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $1.26</a>.</p>
<p>The company reported sales of $5.32 billion, almost in line with the consensus of $5.33 billion, up 2% on both a reported and organic basis year-over-year. Revenue growth was driven by Advanced Visualization Solutions (AVS) and Pharmaceutical Diagnostics (PDx), with <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43687546/ge-healthcare-reports-fourth-quarter-and-full-year-2024-financial-results" rel="noreferrer noopener">overall strength in the U.S</a>.</p>
<p>It clocked 2024 revenues of&nbsp;$19.7 billion, which&nbsp;increased by 1% on both a reported and Organic basis year-over-year. Revenue growth in the&nbsp;U.S.&nbsp;and in PDx was partially offset by continued market softness in&nbsp;China.</p>
<p>Total company book-to-bill was 1.09 times. Total company orders increased 6% organically year-over-year.</p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/41877517/ge-healthcare-and-deephealth-team-up-to-advance-ai-powered-breast-cancer-screening" rel="noreferrer noopener">GE HealthCare And DeepHealth Team Up To Advance AI-Powered Breast Cancer Screening: Details</a></strong></p>
<p>Net income attributable to GE HealthCare was $720 million compared to $403 million a year ago, and Adjusted EBIT was $994 million compared to $837 million.</p>
<p>GE HealthCare President and CEO Peter Arduini said, &#8220;We were pleased with the strong momentum in orders, backlog and book-to-bill that we saw in the fourth quarter. We also continued to deliver revenue growth driven by demand in our Advanced Visualization Solutions and Pharmaceutical Diagnostics businesses, with overall strength in the U.S., and robust margin expansion and earnings growth.&#8221;</p>
<p><strong>Guidance: </strong>GE HealthCare introduces 2025 full-year guidance, which includes the estimated impact of recently implemented U.S. tariffs on products from China.</p>
<ul>
<li>The company expects organic revenue growth of 2% to 3% year over year, reflecting continued demand for products and services and a measured view of market conditions in China.</li>
<li>Adjusted EBIT margin is expected to be 16.7%-16.8%.</li>
<li>The company expects adjusted EPS of $4.61-$4.75 compared to the consensus of $4.66, with free cash flow of at least $1.75 billion.</li>
</ul>
<p><strong>Price Action:</strong> GEHC stock is up 9.01% at $93.64 at the last check Thursday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/25/02/43695619/honda-calls-off-nissan-merger-reports-89-sales-growth-maintains-profit-outlook-despite-lower-eps" target="_blank" rel="noreferrer noopener">Honda Calls Off Nissan Integration, Reports 8.9% Sales Growth: Details</a></strong></li>
</ul>
<p><em>Photo: PixelBiss via Shutterstock</em></p>


Earnings

Health Care

Trading Ideas

GEHC

Why Is GE HealthCare Stock Trading Soaring On Thursday?

EOLS

Trading Halt: Halted at 1:25:00 p.m. ET - Trading Halt: Halt News Pending

WIIM

MYNA

Mynaric shares are trading lower after company announced it received a delisting notification from the Nasdaq

BENF

Beneficient shares are trading lower after the company reported a year-over-year decrease in Q3 sales results.

<p>On Thursday, <strong>Moleculin Biotech, Inc.</strong>,&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) stock is surging with a strong session volume of 64.85 million compared to an average volume of 157.048K, as per data from <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">Benzinga Pro</a>.</p>
<p>The company received FDA feedback and guidance on its IND amendment that has allowed a reduction in the size of its Phase 3 pivotal trial protocol evaluating Annamycin in combination with Cytarabine (also known as Ara-C and for which the combination of Annamycin and Ara-C is referred to as AnnAraC) for refractory/relapsed <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43694446/moleculin-receives-positive-fda-guidance-for-acceleration-of-its-registration-enabling-miracle-tri" rel="noreferrer noopener">Acute Myeloid Leukemia patients</a>.</p>
<p>&#8220;While all of the major aspects of the trial remain unchanged, guidance from the FDA recommended an alteration to the statistical plan that will allow us to reduce the size of Part B of our trial by approximately 10%.&nbsp; Moreover, the nature of the feedback helps us move forward quickly to open sites in the US, in addition to the sites we are expecting to open in&nbsp;Europe&nbsp;and the&nbsp;Middle East. All of this supports the pursuit of an accelerated timeline for new drug approval,&#8221; commented&nbsp;Walter Klemp, Chairman and Chief Executive Officer of Moleculin.</p>
<p>The MIRACLE Phase 3 study utilizes an adaptive design whereby the first 75 to 90 subjects will be randomized in Part A of the trial to receive high-dose cytarabine (HiDAC) combined with either placebo, 190 mg/m2 of Annamycin, or 230 mg/m2 of Annamycin, which Annamycin doses were recommended by the FDA in the company&#8217;s <a target="_blank" href="https://www.benzinga.com/general/biotech/23/11/35754813/penny-stock-moleculin-highlights-interim-data-from-blood-cancer-study-with-complete-response-rate" rel="noreferrer noopener">end of Phase&nbsp;1B/2 meeting</a>.</p>
<p>The amended protocol allows for unblinding preliminary primary efficacy data and safety/tolerability of the three arms at 45 subjects, in addition to the conclusion of Part A (at 75 to 90 subjects).</p>
<p>This early unblinding will yield 30 subjects with Annamycin (190mg/m2 and 230/m2) and HiDAC and 15 subjects with just HiDAC.</p>
<p>The company expects to reach the first unblinding (45 subjects) in the second half of 2025 and the second unblinding, which is expected in the first half of 2026.</p>
<p>For Part B of the trial, approximately 220 additional subjects will be randomized to receive either HiDAC plus placebo or HiDAC plus the optimum dose of Annamycin.</p>
<p>Annamycin currently has Fast Track Status and Orphan Drug Designation from the FDA for relapsed or refractory acute myeloid leukemia and soft tissue sarcoma.</p>
<p>Furthermore, Annamycin has an Orphan Drug Designation for relapsed or refractory acute myeloid leukemia from the European Medicines Agency.</p>
<p><strong>Price Action: </strong>MBRX stock is up 426% at $2.21 at last check Thursday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/earnings/25/02/43694382/consumer-giant-unilever-warns-on-slower-start-to-2025-ice-cream-spin-off-moves-forward-with-amsterdam-incorporation" target="_blank" rel="noreferrer noopener">Consumer Giant Unilever Warns On Slower Start To 2025, Ice Cream Spin-Off Moves Forward With Amsterdam Incorporation</a></strong></li>
</ul>


Biotech

MBRX

Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday?

BOXL

Boxlight shares are trading lower after the company announced a 1-for-5 reverse stock split.

<p>Citigroup  analyst Jon Tower   maintains Denny's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DENN#NASDAQ">DENN</a>) with a Buy and lowers the price target from $8 to $7.</p>


Price Target

Analyst Ratings

DENN

Citigroup Maintains Buy on Denny's, Lowers Price Target to $7

<p><a href="https://www.cdc.gov/mmwr/volumes/74/wr/mm7404a2.htm" title="https://www.cdc.gov/mmwr/volumes/74/wr/mm7404a2.htm">https://www.cdc.gov/mmwr/volumes/74/wr/mm7404a2.htm</a></p>


CVAC

MRNA

NVAX

U.S. CDC Report: Evidence Found Of Recent Bird Flu Infections Among 3 Cattle Veterinarians

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>Zillow Gr</strong>.</p>
<p>Looking at options history for Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/Z#NASDAQ">Z</a>) we detected 19 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 26% of the investors opened trades with bullish expectations and 63% with bearish.</p>
<p>From the overall spotted trades, 3 are puts, for a total amount of $121,180 and 16, calls, for a total amount of $623,328.</p>
<h3>Projected Price Targets</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $55.0 to $110.0 for Zillow Gr over the last 3 months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Zillow Gr's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Zillow Gr's whale activity within a strike price range from $55.0 to $110.0 in the last 30 days. </p>
<h3>Zillow Gr 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739470533_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Z</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$12.3</td>
<td>$12.25</td>
<td>$12.25</td>
<td>$70.00</td>
<td>$73.7K</td>
<td>940</td>
<td align="right">512</td>
</tr>
<tr>
<td>Z</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$32.65</td>
<td>$31.45</td>
<td>$32.0</td>
<td>$110.00</td>
<td>$64.0K</td>
<td>0</td>
<td align="right">20</td>
</tr>
<tr>
<td>Z</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$29.7</td>
<td>$28.15</td>
<td>$28.5</td>
<td>$55.00</td>
<td>$48.4K</td>
<td>1.1K</td>
<td align="right">17</td>
</tr>
<tr>
<td>Z</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$12.35</td>
<td>$12.25</td>
<td>$12.25</td>
<td>$70.00</td>
<td>$42.8K</td>
<td>940</td>
<td align="right">279</td>
</tr>
<tr>
<td>Z</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$12.15</td>
<td>$12.15</td>
<td>$12.15</td>
<td>$70.00</td>
<td>$37.6K</td>
<td>940</td>
<td align="right">32</td>
</tr>
</tbody>
</table>
</p>
<h3>About Zillow Gr</h3>
<p>Zillow Group Inc is an Internet-based real estate company that offers its customers an on-demand experience for selling, buying, renting, or financing with transparency and ease The group works with real estate agents, brokers, builders, property managers, and landlords to pair technology with top-notch service. The group has brands such as Zillow, Trulia, StreetEasy, Hotpads, Zillow Rentals, Zillow Home Loans, ShowingTime, Follow Up Boss, Aryeo and others.</p>
<p>Having examined the options trading patterns of Zillow Gr, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Zillow Gr's Current Market Status</h3>
<ul>
<li>With a trading volume of 2,575,646, the price of Z is down by -1.05%, reaching $77.39.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 76 days from now.</li>
</ul>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Zillow Gr, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Decoding Zillow Gr's Options Activity: What's the Big Picture?

<p>Deep-pocketed investors have adopted a bullish approach towards NuScale Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in SMR usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for NuScale Power. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 66% leaning bullish and 33% bearish. Among these notable options, 2 are puts, totaling $65,000, and 7 are calls, amounting to $238,303.</p>
<h3>Predicted Price Range</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $23.5 and $40.0 for NuScale Power, spanning the last three months.</p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for NuScale Power options trades today is 951.0 with a total volume of 1,488.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for NuScale Power's big money trades within a strike price range of $23.5 to $40.0 over the last 30 days.</p>
<h3>NuScale Power Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739470528_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>SMR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$1.7</td>
<td>$1.48</td>
<td>$1.54</td>
<td>$26.00</td>
<td>$46.2K</td>
<td>1.7K</td>
<td align="right">715</td>
</tr>
<tr>
<td>SMR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/14/25</td>
<td>$13.3</td>
<td>$12.85</td>
<td>$13.0</td>
<td>$38.00</td>
<td>$39.0K</td>
<td>63</td>
<td align="right">30</td>
</tr>
<tr>
<td>SMR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$4.45</td>
<td>$4.2</td>
<td>$4.39</td>
<td>$30.00</td>
<td>$37.6K</td>
<td>3.2K</td>
<td align="right">156</td>
</tr>
<tr>
<td>SMR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$6.35</td>
<td>$5.35</td>
<td>$6.0</td>
<td>$40.00</td>
<td>$36.0K</td>
<td>920</td>
<td align="right">61</td>
</tr>
<tr>
<td>SMR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$3.6</td>
<td>$3.45</td>
<td>$3.6</td>
<td>$26.00</td>
<td>$32.2K</td>
<td>203</td>
<td align="right">94</td>
</tr>
</tbody>
</table>
</p>
<h3>About NuScale Power</h3>
<p>NuScale Power Corp is engaged in the development of a new modular light water reactor nuclear power plant to supply energy for electrical generation, district heating, desalination, hydrogen production, and other process heat applications.</p>
<p>Following our analysis of the options activities associated with NuScale Power, we pivot to a closer look at the company's own performance.</p>
<h3>Current Position of NuScale Power</h3>
<ul>
<li>Currently trading with a volume of 8,011,852, the SMR's price is down by -8.19%, now at $24.24. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 14 days.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for NuScale Power with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


NuScale Power Unusual Options Activity

PIII

P3 Health Partners shares are trading higher. The company issued FY25 guidance.

<p>Financial giants have made a conspicuous bearish move on Lucid Gr. Our analysis of options history for Lucid Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) revealed 10 unusual trades.</p>
<p>Delving into the details, we found 10% of traders were bullish, while 80% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $192,162, and 7 were calls, valued at $562,383.</p>
<h3>Predicted Price Range</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $0.5 to $4.0 for Lucid Gr during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In terms of liquidity and interest, the mean open interest for Lucid Gr options trades today is 8508.75 with a total volume of 39,752.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Lucid Gr's big money trades within a strike price range of $0.5 to $4.0 over the last 30 days.</p>
<h3>Lucid Gr Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739470523_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>LCID</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/21/26</td>
<td>$1.41</td>
<td>$1.2</td>
<td>$1.3</td>
<td>$4.00</td>
<td>$377.0K</td>
<td>4.4K</td>
<td>3.0K</td>
</tr>
<tr>
<td>LCID</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$0.33</td>
<td>$0.32</td>
<td>$0.33</td>
<td>$3.00</td>
<td>$124.5K</td>
<td>27.1K</td>
<td>4.7K</td>
</tr>
<tr>
<td>LCID</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$1.2</td>
<td>$1.17</td>
<td>$1.2</td>
<td>$3.50</td>
<td>$39.0K</td>
<td>1.2K</td>
<td>330</td>
</tr>
<tr>
<td>LCID</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/28/25</td>
<td>$0.39</td>
<td>$0.38</td>
<td>$0.39</td>
<td>$3.00</td>
<td>$37.1K</td>
<td>7.5K</td>
<td>3.2K</td>
</tr>
<tr>
<td>LCID</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$0.95</td>
<td>$0.77</td>
<td>$0.76</td>
<td>$2.50</td>
<td>$34.2K</td>
<td>3.2K</td>
<td>4</td>
</tr>
</tbody>
</table>
</p>
<h3>About Lucid Gr</h3>
<p>Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.</p>
<p>Following our analysis of the options activities associated with Lucid Gr, we pivot to a closer look at the company's own performance.</p>
<h3>Where Is Lucid Gr Standing Right Now?</h3>
<ul>
<li>With a volume of 102,828,117, the price of LCID is up 13.41% at $3.25. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 12 days.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Lucid Gr options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


LCID

Check Out What Whales Are Doing With LCID

<p>Citigroup  analyst Patrick Cunningham   maintains DuPont de Nemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) with a Buy and raises the price target from $88 to $95.</p>


Citigroup Maintains Buy on DuPont de Nemours, Raises Price Target to $95

<p><a href="https://x.com/narendramodi/status/1890100201496748210" title="https://x.com/narendramodi/status/1890100201496748210">https://x.com/narendramodi/status/1890100201496748210</a></p>


Macro Economic Events

Global

Economics

INDA

TSLA

India PM Narendra Modi Posts On X "Had a very good meeting with @elonmusk in Washington DC. We discussed various issues, including those he is passionate about such as space, mobility, technology and innovation. I talked about India's efforts towards reform and furthering 'Minimum Government, Maximum Governance.'"

KELYA

Kelly Services shares are trading higher after the company reported better-than-expected Q4 financial results.

<p>Citigroup  analyst Michael Rollins   maintains Crown Castle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCI#NYSE">CCI</a>) with a Buy and lowers the price target from $128 to $106.</p>


Citigroup Maintains Buy on Crown Castle, Lowers Price Target to $106

PLRX

Pliant Therapeutics shares are trading higher after the company announced it initiated the assembly of an outside expert panel to review unblinded data from the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis.

GeneDx shares are trading higher after the company announced UltraRapid Whole Genome Sequencing, which will deliver actionable results in as soon as 48 hours.

GPRE

President Trump Memo On Reciprocal Tariffs To Mention Brazil Ethanol Tariffs

<p>Citigroup  analyst Atif Malik   maintains Cisco Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) with a Buy and raises the price target from $68 to $71.</p>


CSCO

Citigroup Maintains Buy on Cisco Systems, Raises Price Target to $71

Shares of Polestar ($PSNY) are down 12% after the electric vehicle maker delayed the timeline for it to achieve profitability. The Swedish automake...

Polestar (PSNY) Stock Crashes as EV Maker Delays Profitability

In a report released today, Dan Levy from Barclays assigned a Sell rating to Polestar Automotive Holding UK (PSNY – Research Report), with a price ...

Polestar Automotive Holding UK (PSNY) Gets a Sell from Barclays

In a report released today, Daniel Roeska from Bernstein maintained a Sell rating on Polestar Automotive Holding UK (PSNY – Research Report), with ...

Polestar Automotive Holding UK (PSNY) Gets a Sell from Bernstein

Bank of America Securities analyst John Babcock reiterated a Hold rating on Polestar Automotive Holding UK (PSNY – Research Report) today and set a...

Cautious Outlook for Polestar: Hold Rating Maintained Amid Regulatory and Market Challenges

Polestar: It Keeps Getting Worse

Bernstein analyst Daniel Roeska raised the firm's price target on Polestar (PSNY) to 40c from 33c and keeps an Underperform rating on the shares. P...

Polestar price target raised to 40c from 33c at Bernstein

Michael Lohscheller, the CEO of EV manufacturer Polestar ($PSNY), said in an interview with Bloomberg that Elon Musk‘s increasing involvement in gl...

Polestar (PSNY) CEO Says that Elon Musk's Politics Are an Opportunity

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President ...

Trump Trade: U.S. and Colombia reach deal, tariffs on hold

Audio pioneer Dolby Laboratories ($DLB) has made significant strides recently. The company has partnered with brands such as Harmon Kardon, Samsung...

Dolby Laboratories (DLB) Forges Partnerships and Sounding Sharp for Q1 of 2025

EV Company News For The Month Of January 2025

AMZN

ASUUY

AYRO

BATT

BCCMY

BLBD

BLNK

BMCLF

BYDDF

BYDDY

DELL

DNFGF

DNFGY

EVTV

FUJHF

FUJHY

GELYF

GELYY

GOOG

GOOGL

GWLLF

GWLLY

HISEF

HNDAF

HYLN

HYMTF

KNDI

LAAOF

MAHMF

MBGAF

MBGYY

MMTOF

MZDAF

MZDAY

NIOIF

NSANF

NSANY

NXPI

ORCL

PCRFF

PLUG

POAHF

POAHY

PSNYW

RACE

RDDT

RIVN

RNLSY

RNSDF

SHCAY

SNAP

SONY

STLA

SZKMF

SZKMY

TCLHF

TOYOF

VFSWW

VLKAF

VLKPF

VLVLY

VWAGY

VWAPY

WKHS

XIACF

XIACY

XPEV

XPNGF

Press Releases

PSNY INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Polestar Automotive Holding UK PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Penny Stocks

PSNY Investors Have Opportunity to Lead Polestar Automotive Holding UK PLC Securities Fraud Lawsuit with the Schall Law Firm

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Polestar Automotive

Nextracker Inc. Class Action Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey against Polestar Automotive Holding UK PLC

PSNY Investors Have Opportunity to Lead Polestar Automotive Holding UK PLC Securities Fraud Lawsuit Filed by The Rosen Law Firm

Legal

ROSEN, A LEADING NATIONAL FIRM, Encourages Polestar Automotive Holding UK PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – PSNY

Polestar Automotive Holding UK PLC Stockholders with Large Losses Should Contact Robbins LLP for Information About the PSNY Class Action Lawsuit

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Grocery Outlet, Polestar, Arconic, and IAS and Encourages Investors to Contact the Firm

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Polestar Automotive

Thunder Power Holdings, Inc. - Common Stock

Thunder Power Holdings

Cenntro

Chijet Motor Company, Inc. - Ordinary Shares

Chijet Motor Co

ECD Automotive Design, Inc. - Common Stock

ECD Automotive Design

Ford Motor

Faraday Future Intelligent Electric Inc. - Class A Common Stock

Faraday Future

Fly-E Group

General Motors

Honda Motor Co

Lucid Gr

Li Auto Inc. - American Depositary Shares

Li Auto

Lotus Technology Inc. - American Depositary Shares

Lotus Technology

Mullen Automotive

NIO Inc. American depositary shares, each representing one Class A ordinary share

NWTN

Rivian Automotive, Inc. - Class A Common Stock

Rivian Automotive

Comments

Polestar Automotive

Polestar Automotive (PSNY) Opciones

Polestar Automotive (NASDAQ:PSNY) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL